WEST PHARMACEUTICAL SERVICES, INC. OCI, before Reclassifications, Net of Tax, Attributable to Parent
WEST PHARMACEUTICAL SERVICES, INC. (WST) reported OCI, before Reclassifications, Net of Tax, Attributable to Parent of -$36.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent · last filed 2026-07-23
- WEST PHARMACEUTICAL SERVICES, INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2026-06-30 was -$16.00M, a 113.68% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2026-03-31 was -$20.20M, a 138.62% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2025-12-31 was -$3.60M.
- WEST PHARMACEUTICAL SERVICES, INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2025-09-30 was -$13.30M, a 116.56% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2025 was $152.40M.
- WEST PHARMACEUTICAL SERVICES, INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2024 was -$116.60M, a 441.94% decline from fiscal 2023.
- WEST PHARMACEUTICAL SERVICES, INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2023 was $34.10M.
- WEST PHARMACEUTICAL SERVICES, INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2022 was -$56.00M.
| Period end | OCI, before Reclassifications, Net of Tax, Attributable to Parent 3 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 6 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 9 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$16.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | -$36.20M 10-Q · filed 2026-07-23 | -$39.80M derived: sum of 3 quarters · filed 2026-07-23 | -$53.10M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | -$20.20M 10-Q · filed 2026-04-23 | -$23.80M derived: sum of 2 quarters · filed 2026-04-23 | -$37.10M derived: sum of 3 quarters · filed 2026-04-23 | $79.90M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | -$3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$16.90M derived: sum of 2 quarters · filed 2026-02-17 | $100.10M derived: sum of 3 quarters · filed 2026-07-23 | $152.40M 10-K · filed 2026-02-17 |
| 2025-09-30 | -$13.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $103.70M derived: sum of 2 quarters · filed 2026-07-23 | $156.00M 10-Q · filed 2025-10-23 | $33.60M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $117.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $169.30M 10-Q · filed 2026-07-23 | $46.90M derived: sum of 3 quarters · filed 2026-07-23 | $127.20M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $52.30M 10-Q · filed 2026-04-23 | -$70.10M derived: sum of 2 quarters · filed 2026-04-23 | $10.20M derived: sum of 3 quarters · filed 2026-04-23 | -$14.80M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | -$122.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$42.10M derived: sum of 2 quarters · filed 2026-02-17 | -$67.10M derived: sum of 3 quarters · filed 2026-02-17 | -$116.60M 10-K · filed 2026-02-17 |
| 2024-09-30 | $80.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $55.30M derived: sum of 2 quarters · filed 2025-10-23 | $5.80M 10-Q · filed 2025-10-23 | $85.80M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | -$25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-24 | -$74.50M 10-Q · filed 2025-07-24 | $5.50M derived: sum of 3 quarters · filed 2026-02-17 | -$37.30M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | -$49.50M 10-Q · filed 2025-04-24 | $30.50M derived: sum of 2 quarters · filed 2026-02-17 | -$12.30M derived: sum of 3 quarters · filed 2026-02-17 | -$29.60M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $80.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $37.20M derived: sum of 2 quarters · filed 2026-02-17 | $19.90M derived: sum of 3 quarters · filed 2026-02-17 | $34.10M 10-K · filed 2026-02-17 |
| 2023-09-30 | -$42.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-24 | -$60.10M derived: sum of 2 quarters · filed 2024-10-24 | -$45.90M 10-Q · filed 2024-10-24 | $61.40M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | -$17.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-25 | -$3.10M 10-Q · filed 2024-07-25 | $104.20M derived: sum of 3 quarters · filed 2025-02-18 | $28.20M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $14.20M 10-Q · filed 2024-04-25 | $121.50M derived: sum of 2 quarters · filed 2025-02-18 | $45.50M derived: sum of 3 quarters · filed 2025-02-18 | -$18.20M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $107.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $31.30M derived: sum of 2 quarters · filed 2025-02-18 | -$32.40M derived: sum of 3 quarters · filed 2025-02-18 | -$56.00M 10-K · filed 2025-02-18 |
| 2022-09-30 | -$76.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | -$139.70M derived: sum of 2 quarters · filed 2023-10-26 | -$163.30M 10-Q · filed 2023-10-26 | -$166.90M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$63.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-27 | -$87.30M 10-Q · filed 2023-07-27 | -$90.90M derived: sum of 3 quarters · filed 2024-02-20 | -$113.20M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$23.60M 10-Q · filed 2023-04-27 | -$27.20M derived: sum of 2 quarters · filed 2024-02-20 | -$49.50M derived: sum of 3 quarters · filed 2024-02-20 | -$45.10M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$25.90M derived: sum of 2 quarters · filed 2024-02-20 | -$21.50M derived: sum of 3 quarters · filed 2024-02-20 | -$52.40M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$22.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | -$17.90M derived: sum of 2 quarters · filed 2022-10-27 | -$48.80M 10-Q · filed 2022-10-27 | $400.00K derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $4.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | -$26.50M 10-Q · filed 2022-07-28 | $22.70M derived: sum of 3 quarters · filed 2023-02-21 | $50.70M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | -$30.90M 10-Q · filed 2022-04-28 | $18.30M derived: sum of 2 quarters · filed 2023-02-21 | $46.30M derived: sum of 3 quarters · filed 2023-02-21 | |
| 2020-12-31 | $49.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $77.20M derived: sum of 2 quarters · filed 2023-02-21 | $40.60M 10-K · filed 2023-02-21 | |
| 2020-09-30 | $28.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-23 | -$8.60M 10-Q · filed 2020-10-23 | ||
| 2020-06-30 | -$36.60M 10-Q · filed 2020-07-24 | |||
| 2019-12-31 | $8.40M 10-K · filed 2022-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |